Seres Therapeutics News

Seres Therapeutics Price Target Maintained With a $10.00/Share by Canaccord Genuity

Dow JonesNov 15 00:21

Seres Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow JonesNov 15 00:21

Promising Developments and Financial Stability Drive Buy Rating for Seres Therapeutics

TipRanksNov 14 20:30

Seres Therapeutics Analyst Ratings

BenzingaNov 14 07:57

Chardan Capital Maintains Buy on Seres Therapeutics, Maintains $1.25 Price Target

BenzingaNov 14 07:57

TD Cowen Maintains Seres Therapeutics(MCRB.US) With Buy Rating

Futu NewsNov 14 00:32

Seres Therapeutics (MCRB) Gets a Buy From TD Cowen

TipRanksNov 13 23:58

Seres Therapeutics Analyst Ratings

BenzingaOct 24 19:09

J.P. Morgan Downgrades Seres Therapeutics(MCRB.US) to Sell Rating

Futu NewsOct 24 06:31

Canaccord Genuity Maintains Buy on Seres Therapeutics, Maintains $10 Price Target

BenzingaSep 14 02:39

Seres Therapeutics Analyst Ratings

BenzingaSep 14 02:38

Oppenheimer Maintains Seres Therapeutics(MCRB.US) With Hold Rating

Futu NewsSep 13 20:31

Oppenheimer Sticks to Their Hold Rating for Seres Therapeutics (MCRB)

TipRanksSep 13 19:47

CCORF Maintains Seres Therapeutics(MCRB.US) With Buy Rating, Maintains Target Price $10

Futu NewsSep 13 19:31

Analysts Offer Insights on Healthcare Companies: Seres Therapeutics (MCRB), BioMarin Pharmaceutical (BMRN) and Exact Sciences (EXAS)

TipRanksSep 13 19:10

Chardan Capital Maintains Seres Therapeutics(MCRB.US) With Buy Rating, Maintains Target Price $1.25

Futu NewsSep 13 10:31

Buy Rating Affirmed for Seres Therapeutics' SER-155 Amid Anticipated Positive Impact on Infection and GvHD Rates

TipRanksAug 22 18:57

TD Cowen Maintains Seres Therapeutics(MCRB.US) With Buy Rating

Futu NewsAug 15 18:36

Oppenheimer Maintains Seres Therapeutics(MCRB.US) With Hold Rating

Futu NewsAug 15 14:32

Seres Therapeutics Price Target Maintained With a $10.00/Share by Canaccord Genuity

Dow JonesAug 14 21:57